Search tool

Transmitted through the sharing of needles, syringes and other injecting equipment, hepatitis C is the most common infectious disease among injecting drug users in Europe today.In this analysis, the EMCDDA looks at...

The number and diversity of new psychoactive substances reported in Europe in recent years represents a major challenge for Europe’s policymakers. This analysis looks at countries’ legal responses to the new drugs...

Three United Nations Conventions provide the international legal framework on drug control, instructing countries to limit drug supply and use to medical and scientific purposes. Yet, debate is increasing on the legalisation...

The use of substitution drugs for the treatment of opioid dependence represents a key evidence-based response to heroin problems in Europe. However, the diversion of these medicines from their intended use in...

Psychosocial interventions are structured psychological or social interventions used to address substance-related problems. They can be used at different stages of drug treatment to identify the problem, treat it and assist with...

A journalists’ guide to upcoming events and products from the EU drugs agency in Lisbon, May 2016.

This report explores the recent resurgence in use of MDMA in Europe and increased availability of high-strength MDMA tablets, crystals and powders. It notes that the picture is not uniform across European...

April–June 2016​ In this issue: 2016 EU Drug Markets Report | Monitoring illicit drugs in wastewater | UNGASS 2016 | Strengthening early warning on new synthetic opioids | New EMCDDA products and...